Department of Clinical Laboratory, Yongzhou Central Hospital, Yongzhou, China.
Department of Clinical Laboratory, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, China.
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231177809. doi: 10.1177/15330338231177809.
Owing to the mortality associated with metastatic prostate cancer and the shortcomings of the current parameters in predicting the disease prognosis, we require the identification of viable biomarkers, which would help in the diagnosis and prognosis of the disease. We aimed to determine whether the interleukin-8 level in the tumor microenvironment could serve as a potential clinical diagnostic marker and prognostic factor for prostate cancer.
The migration assay of prostate cancer cells was performed in an in vitro co-culture model. Cell lines PC3 and DU145 were divided into two groups and co-cultured with M0 and M2 macrophages, respectively. We used reverse transcription-quantitative polymerase chain reaction to detect M2 macrophage marker expression levels. Immunohistochemistry analyses of tissue microarrays were performed to analyze the correlation between the increased expression of interleukin-8 and the prognosis of prostate cancer. A retrospective analysis based on 142 residual serum specimens was performed to analyze the level of interleukin-8.
We observed that M2 macrophages promoted the migration of prostate cancer cells and significantly increased the concentrations of interleukin-8 in the co-culture supernatants. We observed increased expression of CD163 and interleukin-8 in prostate cancer tissues. Furthermore, the levels of interleukin-8 in the serum of prostate cancer patients were higher than those in healthy controls. Untreated patients had higher levels of interleukin-8, which could be a predictor of a higher metastasis rate.
These results suggest that interleukin-8 produced via bidirectional communication between prostate cancer cells and M2 macrophages is a putative biomarker for prostate cancer diagnosis and treatment.
由于转移性前列腺癌的死亡率以及当前预测疾病预后的参数存在缺陷，我们需要确定可行的生物标志物，以帮助诊断和预测疾病。我们旨在确定肿瘤微环境中的白细胞介素-8 水平是否可以作为前列腺癌的潜在临床诊断标志物和预后因素。
在体外共培养模型中进行前列腺癌细胞的迁移分析。将前列腺癌细胞系 PC3 和 DU145 分为两组，分别与 M0 和 M2 巨噬细胞共培养。我们使用逆转录定量聚合酶链反应检测 M2 巨噬细胞标志物的表达水平。通过组织微阵列的免疫组织化学分析来分析白细胞介素-8 表达增加与前列腺癌预后之间的相关性。对 142 份剩余血清标本进行回顾性分析，以分析白细胞介素-8 的水平。
我们观察到 M2 巨噬细胞促进了前列腺癌细胞的迁移，并显著增加了共培养上清液中白细胞介素-8 的浓度。我们观察到前列腺癌组织中 CD163 和白细胞介素-8 的表达增加。此外，前列腺癌患者血清中的白细胞介素-8 水平高于健康对照组。未经治疗的患者白细胞介素-8 水平较高，这可能是转移率较高的预测指标。
这些结果表明，前列腺癌细胞与 M2 巨噬细胞之间双向通讯产生的白细胞介素-8 是前列腺癌诊断和治疗的潜在生物标志物。
